Coronavirus Update: J&J Pauses COVID-19 Vaccine Trial After Unexplained Illness
Plus: China Starts Vaccines Pre-Order
J&J becomes the second company to pause a COVID-19 vaccine trial, releasing few details but emphasizing the measure's precautionary nature.
You may also be interested in...
The company is on track to provide hundreds of millions of doses of its COVID-19 vaccine in the first half of 2021, Gorsky reaffirmed during the Milken Institute Future of Health Summit.
Patient confidentiality and trial blinding precluded a Janssen official from sharing specifics about the safety event that led to a study enrollment pause, but Advisory Committee on Immunization Practices representatives say the lack of detailed, publicly disclosed information is not helping vaccine confidence.
NIH study of monoclonal antibody therapy in combination with Gilead's remdesivir paused for safety reasons.